ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Immune Modulation Therapy and Imaging: Workshop Report.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.Nature reviews. Clinical oncology · 2019Guideline
- Mechanism and intervention strategy of thymus atrophy in cancer immunotherapy.American journal of cancer research · 2026Review
- Phenomic Imaging.Phenomics (Cham, Switzerland) · 2023Review
- The role of clinical imaging in oncology drug development: progress and new challenges.The British journal of radiology · 2023Review
- F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.Annals of nuclear medicine · 2022Article
- Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI.European radiology · 2021Article
- Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival.European radiology · 2021Article
- [Monitoring of immunotherapy : Possibilities and limitations].Der Radiologe · 2020Review
- Article
- Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction.Cancer medicine · 2019Review
- Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.European radiology · 2019Article
- Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.Clinical pharmacology and therapeutics · 2019Review
- Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.Cancer research · 2019Article
- The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.Nature reviews. Clinical oncology · 2019Review
- Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.Theranostics · 2019Review
- Role of noninvasive molecular imaging in determining response.Advances in radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 3 countries.
Funding
Abstract
A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.